---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-001915"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:31:21.570302+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q1 net loss $3.8M ($0.13/shr); cash $20.1M, expects funding into Q4 2022

## Summary
- Revenue $68K from Amgen R&D services, down from $157K YoY; operating expenses $3.8M vs $2.4M.
- Cash $20.1M at March 31, 2022 (vs $24.9M Dec 31); expects to fund operations into Q4 2022.
- EB613 (oral PTH for osteoporosis): FDA completed CMC review; Phase 3 trial design underway.
- Market study: >15M U.S. osteoporosis patients, 75% untreated; clinicians favor oral anabolic.
- EB612 hypoparathyroidism: orphan drug status; working on improved formulation for next trial.

## SEC filing metadata
- accession: 0001178913-22-001915
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891322001915/0001178913-22-001915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891322001915/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-001915
- JSON: https://secwatch.observer/filing/0001178913-22-001915.json
- Plain text: https://secwatch.observer/filing/0001178913-22-001915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.